$KITE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Kite Pharma, Inc.. Get notifications about new insider transactions in Kite Pharma, Inc. for free.
Page: < prev 1 ... 2 3 4 5 6 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 65.38 | 432 | 28,244 | 2,941 | 3.4 K to 2.9 K (-12.81 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 64.64 | 3,352 | 216,673 | 3,373 | 6.7 K to 3.4 K (-49.84 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 63.73 | 2,410 | 153,589 | 6,725 | 9.1 K to 6.7 K (-26.38 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 62.70 | 3,373 | 211,487 | 9,135 | 12.5 K to 9.1 K (-26.97 %) |
| Dec 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 12,508 | 2.9 K to 12.5 K (+325.30 %) |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 78,000 | |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 82.42 | 90 | 7,418 | 1,888 | 2 K to 1.9 K (-4.55 %) |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 80.59 | 100 | 8,059 | 1,978 | 2.1 K to 2 K (-4.81 %) |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 78.53 | 254 | 19,947 | 2,078 | 2.3 K to 2.1 K (-10.89 %) |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 77.50 | 1,215 | 94,163 | 2,332 | 3.5 K to 2.3 K (-34.25 %) |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 76.57 | 3,664 | 280,552 | 3,547 | 7.2 K to 3.5 K (-50.81 %) |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 75.48 | 2,772 | 209,231 | 7,211 | 10 K to 7.2 K (-27.77 %) |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 74.53 | 905 | 67,450 | 9,983 | 10.9 K to 10 K (-8.31 %) |
| Dec 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,888 | 1.9 K to 10.9 K (+476.69 %) |
| Nov 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 15,000 | 20,250 | 345,394 | |
| Nov 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 86.90 | 2,600 | 225,940 | 75,507 | 78.1 K to 75.5 K (-3.33 %) |
| Nov 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 86.35 | 12,400 | 1,070,740 | 78,107 | 90.5 K to 78.1 K (-13.70 %) |
| Nov 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 15,000 | 20,250 | 90,507 | 75.5 K to 90.5 K (+19.87 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 645 | 10,965 | 33,878 | |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 5,500 | 3,850 | 102,125 | |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 79.78 | 445 | 35,502 | 2,198 | 2.6 K to 2.2 K (-16.84 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 78.71 | 2,237 | 176,074 | 2,643 | 4.9 K to 2.6 K (-45.84 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 78.02 | 2,463 | 192,163 | 4,880 | 7.3 K to 4.9 K (-33.54 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 76.53 | 1,000 | 76,530 | 7,343 | 8.3 K to 7.3 K (-11.99 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 645 | 10,965 | 8,343 | 7.7 K to 8.3 K (+8.38 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 5,500 | 3,850 | 7,698 | 2.2 K to 7.7 K (+250.23 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 112,000 | |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 80.20 | 90 | 7,218 | 6,342 | 6.4 K to 6.3 K (-1.40 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 79.25 | 741 | 58,724 | 6,432 | 7.2 K to 6.4 K (-10.33 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 78.55 | 4,598 | 361,173 | 7,173 | 11.8 K to 7.2 K (-39.06 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 77.65 | 2,159 | 167,646 | 11,771 | 13.9 K to 11.8 K (-15.50 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 76.43 | 1,412 | 107,919 | 13,930 | 15.3 K to 13.9 K (-9.20 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 9,000 | 62,010 | 15,342 | 6.3 K to 15.3 K (+141.91 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 133,031 | |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 80.27 | 172 | 13,806 | 2,941 | 3.1 K to 2.9 K (-5.53 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 79.27 | 944 | 74,831 | 3,113 | 4.1 K to 3.1 K (-23.27 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 78.49 | 5,236 | 410,974 | 4,057 | 9.3 K to 4.1 K (-56.34 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 77.62 | 1,791 | 139,017 | 9,293 | 11.1 K to 9.3 K (-16.16 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 76.46 | 1,424 | 108,879 | 11,084 | 12.5 K to 11.1 K (-11.38 %) |
| Nov 18 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 12,508 | 2.9 K to 12.5 K (+325.30 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 5,000 | 6,750 | 360,394 | |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 80.00 | 5,000 | 400,000 | 75,507 | 80.5 K to 75.5 K (-6.21 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 5,000 | 6,750 | 80,507 | 75.5 K to 80.5 K (+6.62 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 30,800 | 212,212 | 223,000 | |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 80.02 | 30,800 | 2,464,616 | 6,904 | 37.7 K to 6.9 K (-81.69 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 30,800 | 212,212 | 37,704 | 6.9 K to 37.7 K (+446.12 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 87,000 | |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 72.41 | 110 | 7,965 | 1,888 | 2 K to 1.9 K (-5.51 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 71.64 | 4,899 | 350,964 | 1,998 | 6.9 K to 2 K (-71.03 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 70.87 | 2,876 | 203,822 | 6,897 | 9.8 K to 6.9 K (-29.43 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 69.81 | 525 | 36,650 | 9,773 | 10.3 K to 9.8 K (-5.10 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 68.22 | 590 | 40,250 | 10,298 | 10.9 K to 10.3 K (-5.42 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,888 | 1.9 K to 10.9 K (+476.69 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 253,800 | |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 71.70 | 3,923 | 281,279 | 6,904 | 10.8 K to 6.9 K (-36.23 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 70.96 | 2,800 | 198,688 | 10,827 | 13.6 K to 10.8 K (-20.55 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 69.52 | 500 | 34,760 | 13,627 | 14.1 K to 13.6 K (-3.54 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 68.27 | 477 | 32,565 | 14,127 | 14.6 K to 14.1 K (-3.27 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 14,604 | 6.9 K to 14.6 K (+111.53 %) |
| Oct 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 365,394 | |
| Oct 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 71.01 | 500 | 35,505 | 75,507 | 76 K to 75.5 K (-0.66 %) |
| Oct 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 70.23 | 4,400 | 309,012 | 76,007 | 80.4 K to 76 K (-5.47 %) |
| Oct 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 69.53 | 5,100 | 354,603 | 80,407 | 85.5 K to 80.4 K (-5.96 %) |
| Oct 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 85,507 | 75.5 K to 85.5 K (+13.24 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 142,598 | |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 64.08 | 878 | 56,262 | 2,941 | 3.8 K to 2.9 K (-22.99 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 63.32 | 2,475 | 156,717 | 3,819 | 6.3 K to 3.8 K (-39.32 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 62.41 | 4,377 | 273,169 | 6,294 | 10.7 K to 6.3 K (-41.02 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 61.54 | 1,442 | 88,741 | 10,671 | 12.1 K to 10.7 K (-11.90 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 60.36 | 395 | 23,842 | 12,113 | 12.5 K to 12.1 K (-3.16 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 12,508 | 2.9 K to 12.5 K (+325.30 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 121,000 | |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 64.19 | 465 | 29,848 | 6,342 | 6.8 K to 6.3 K (-6.83 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 63.50 | 2,007 | 127,445 | 6,807 | 8.8 K to 6.8 K (-22.77 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 62.54 | 4,702 | 294,063 | 8,814 | 13.5 K to 8.8 K (-34.79 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 61.61 | 1,375 | 84,714 | 13,516 | 14.9 K to 13.5 K (-9.23 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 60.42 | 451 | 27,249 | 14,891 | 15.3 K to 14.9 K (-2.94 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 9,000 | 62,010 | 15,342 | 6.3 K to 15.3 K (+141.91 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 645 | 10,965 | 34,523 | |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 5,500 | 3,850 | 107,625 | |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 64.25 | 84 | 5,397 | 2,198 | 2.3 K to 2.2 K (-3.68 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 63.60 | 1,600 | 101,760 | 2,282 | 3.9 K to 2.3 K (-41.22 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 62.62 | 2,800 | 175,336 | 3,882 | 6.7 K to 3.9 K (-41.90 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 61.79 | 1,300 | 80,327 | 6,682 | 8 K to 6.7 K (-16.29 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 60.08 | 361 | 21,689 | 7,982 | 8.3 K to 8 K (-4.33 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 645 | 10,965 | 8,343 | 7.7 K to 8.3 K (+8.38 %) |
| Oct 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 5,500 | 3,850 | 7,698 | 2.2 K to 7.7 K (+250.23 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 261,500 | |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.11 | 7,700 | 424,347 | 6,904 | 14.6 K to 6.9 K (-52.73 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 14,604 | 6.9 K to 14.6 K (+111.53 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 96,000 | |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 57.10 | 74 | 4,225 | 1,888 | 2 K to 1.9 K (-3.77 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 56.43 | 1,454 | 82,049 | 1,962 | 3.4 K to 2 K (-42.56 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 55.37 | 1,263 | 69,932 | 3,416 | 4.7 K to 3.4 K (-26.99 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 54.47 | 5,079 | 276,653 | 4,679 | 9.8 K to 4.7 K (-52.05 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 53.51 | 1,130 | 60,466 | 9,758 | 10.9 K to 9.8 K (-10.38 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,888 | 1.9 K to 10.9 K (+476.69 %) |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 375,394 | |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 56.70 | 3,640 | 206,388 | 75,507 | 79.1 K to 75.5 K (-4.60 %) |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 55.91 | 3,560 | 199,040 | 79,147 | 82.7 K to 79.1 K (-4.30 %) |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 54.73 | 2,800 | 153,244 | 82,707 | 85.5 K to 82.7 K (-3.27 %) |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 85,507 | 75.5 K to 85.5 K (+13.24 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 130,000 | |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 64.69 | 4,440 | 287,224 | 6,342 | 10.8 K to 6.3 K (-41.18 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 63.99 | 4,560 | 291,794 | 10,782 | 15.3 K to 10.8 K (-29.72 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | M | 6.89 | 9,000 | 62,010 | 15,342 | 6.3 K to 15.3 K (+141.91 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 152,165 | |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 65.28 | 128 | 8,356 | 2,941 | 3.1 K to 2.9 K (-4.17 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 64.66 | 5,165 | 333,969 | 3,069 | 8.2 K to 3.1 K (-62.73 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 63.97 | 4,274 | 273,408 | 8,234 | 12.5 K to 8.2 K (-34.17 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 12,508 | 2.9 K to 12.5 K (+325.30 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 645 | 10,965 | 35,168 | |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 5,500 | 3,850 | 113,125 | |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 64.66 | 3,181 | 205,683 | 2,198 | 5.4 K to 2.2 K (-59.14 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 63.98 | 2,964 | 189,637 | 5,379 | 8.3 K to 5.4 K (-35.53 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 645 | 10,965 | 8,343 | 7.7 K to 8.3 K (+8.38 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 5,500 | 3,850 | 7,698 | 2.2 K to 7.7 K (+250.23 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Option Exercise | A | 56.12 | 20,000 | 1,122,400 | 20,000 | |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,384 | 50,876 | 269,200 | |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 316 | 2,177 | 276,584 | |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.00 | 7,384 | 406,120 | 6,904 | 14.3 K to 6.9 K (-51.68 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,384 | 50,876 | 14,288 | 6.9 K to 14.3 K (+106.95 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.00 | 316 | 17,380 | 6,904 | 7.2 K to 6.9 K (-4.38 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 316 | 2,177 | 7,220 | 6.9 K to 7.2 K (+4.58 %) |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 105,000 | |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 52.90 | 269 | 14,230 | 1,888 | 2.2 K to 1.9 K (-12.47 %) |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 52.34 | 3,712 | 194,286 | 2,157 | 5.9 K to 2.2 K (-63.25 %) |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 51.36 | 5,019 | 257,776 | 5,869 | 10.9 K to 5.9 K (-46.10 %) |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,888 | 1.9 K to 10.9 K (+476.69 %) |
| Aug 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 385,394 | |
| Aug 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 54.38 | 1,600 | 87,008 | 75,507 | 77.1 K to 75.5 K (-2.08 %) |
| Aug 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 53.73 | 6,300 | 338,499 | 77,107 | 83.4 K to 77.1 K (-7.55 %) |
| Aug 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 52.69 | 2,100 | 110,649 | 83,407 | 85.5 K to 83.4 K (-2.46 %) |
| Aug 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 85,507 | 75.5 K to 85.5 K (+13.24 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 139,000 | |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 61.83 | 671 | 41,488 | 5,218 | 5.9 K to 5.2 K (-11.39 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 61.16 | 4,918 | 300,785 | 5,889 | 10.8 K to 5.9 K (-45.51 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 60.26 | 3,411 | 205,547 | 10,807 | 14.2 K to 10.8 K (-23.99 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | M | 6.89 | 9,000 | 62,010 | 14,218 | 5.2 K to 14.2 K (+172.48 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 161,732 | |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 61.73 | 1,465 | 90,434 | 1,695 | 3.2 K to 1.7 K (-46.36 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 60.99 | 5,322 | 324,589 | 3,160 | 8.5 K to 3.2 K (-62.74 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 60.21 | 2,780 | 167,384 | 8,482 | 11.3 K to 8.5 K (-24.68 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 11,262 | 1.7 K to 11.3 K (+564.42 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 645 | 10,965 | 35,813 | |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 5,500 | 3,850 | 118,625 | |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 61.65 | 1,150 | 70,898 | 999 | 2.1 K to 999 (-53.51 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 60.99 | 3,439 | 209,745 | 2,149 | 5.6 K to 2.1 K (-61.54 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 60.15 | 1,556 | 93,593 | 5,588 | 7.1 K to 5.6 K (-21.78 %) |
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 645 | 10,965 | 7,144 | 6.5 K to 7.1 K (+9.92 %) |